Deep Dive: Disruptive Technologies
No other industry would tolerate avoidable annual losses of $637 billion, but that’s exactly what pharma is doing by not investing in adherence. Now is the time to start recovering that revenue.
There are good reasons why patient centricity has become such a well-used term within the pharmaceutical industry. But, says Kantar Health’s Linda VerPlanck, the research approaches underpinning it must be able to deliver transformational insights that can, in turn, improve real-world outcomes.